Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry.

Date publication

mars 2018

Journal

Annals of surgical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr HEYD Bruno

Tous les auteurs :
Votanopoulos KI, Sugarbaker P, Deraco M, Morris D, Glehen O, Elias D, De Simone M, Robella M, Heyd B, Kusamura S, Baratti D, Chouliaras K, Russell G, Shen P, Levine EA,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29260418

Résumé

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has dramatically improved the survival of patients with epithelioid peritoneal mesothelioma. It is unknown if CRS/HIPEC is indicated for the more aggressive biphasic mesothelioma variant.

Mots clés

Chemotherapy, Adjuvant, Chemotherapy, Cancer, Regional Perfusion, mortality, Combined Modality Therapy, Cytoreduction Surgical Procedures, mortality, Female, Follow-Up Studies, Humans, Hyperthermia, Induced, mortality, Male, Mesothelioma, mortality, Middle Aged, Peritoneal Neoplasms, mortality, Prognosis, Registries, statistics & numerical data, Retrospective Studies, Survival Rate

Référence

Ann. Surg. Oncol.. 2018 Mar;25(3):667-673